Previous Next

ARCHIVE

№1' 2020

INFECTIOUS DISEASES

International Medical Journal, Vol. 26., Iss. 1, 2020, P. 72−75.

DOI (https://doi.org/10.37436/2308-5274-2020-1-16)

MICRORNA-122 AS A BIOLOGICAL MARKER OF CHRONIC VIRAL HEPATITIS C

State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine", Dnipro
Bogomolets Institute of Physiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine

New epigenetic markers are being studied in various countries around the world to diagnose, predict, and treat the patients with chronic viral hepatitis C. Epigenetics is currently studying the hereditary changes in gene expression or phenotype that are not related to the changes in DNA sequence. One field of epigenetics is the expression of RNA that does not encode a protein, namely miRNA, which is a molecule 18−22 nucleotides in length that plays a crucial role in regulating gene expression. Circulating miRNAs are a new genetic material that can be isolated from a patient's blood. The expression level of a particular miRNA has different biological and clinical effects. By means of its determination in various miRNAs it is possible to predict development of diseases. In order to study the baseline expression of miRNA−122 in patients with chronic viral hepatitis C with the first HCV genotype, 74 patients were examined. Diagnosis and monitoring of the patients was performed according to the local protocols and bioethical standards. The level of miRNA−122 expression in patients with chronic viral hepatitis C with the first HCV genotype was established by reverse transcription. Studies show that the level of miRNA−122 expression in the patients with HCV and healthy individuals showed significant variability. The obtained data indicate that the expression level of miRNA−122 in patients is 29 times higher than in healthy individuals at p = 0.0001 (U; Z). This can be an additional biomarker as an index of the presence of chronic viral hepatitis C and can be further used in practice. Therefore, the high level of miRNA−122 expression in subjects (≥ 8.771 rel. units (Log10 miR−122 ≥ 0.939 rel. units)) may be the basis for further screening of patients for HCV infection. The prospects of using this index, which will allow to personalize the diagnosis and treatment tactics for patients, that, in turn, will contribute to the implementation of the WHO global strategy for the elimination of viral hepatitis.

Key words: chronic viral hepatitis C, miRNA−122, elimination of viral hepatitis, biological marker.

REFERENCES

1. Zakhvoryuvanіst' na khronіchnii gepatit S u strukturі іnshikh khronіchnikh vіrusnikh gepatitіv u Dnіpropetrovs'komu regіonі ta Ukraїnі / O. P. Shevchenko−Makarenko ta іn. // Vіsn. naukovikh doslіdzhen'. 2018. № 1. S. 156−160. doi: https://doi.org/10.11603/2415−8798.2018.1.8791

2. Shevchenko−Makarenko O. P. Prognoz rozvitku epіdemіchnogo protsesu gepatitu S na 2018−2020 roki v Dnіpropetrovs'komu regіonі ta Ukraїnі // Іnfektsіinі khvorobi. 2018. № 2. S. 28−35. doi: https://doi.org/10.11603/1681−2727.2018.2.9031

3. Maloinvazivnaya diagnostika tyazhesti fibroticheskikh izmenenii pecheni u bol'nykh khronicheskim gepatitom S / V. N. Koz'ko i dr. // Mіzhnarodnii medichnii zhurn. 2019. T. 25, № 1. S. 80−85. URL: http://nbuv.gov.ua/UJRN/Mmzh_2019_25_1_19

4. Porіvnyal'nii analіz vmіstu vіtamіnu D u khvorikh na khronіchnii vіrusnii gepatit S ta zdorovikh / L. R. Shostakovich−Korets'ka ta іn. // Medichnі perspektivi. 2019. T. 24, № 4. S. 94−101. doi: https://doi.org/10.26641/2307−0404.2019.4.189360

5. Bollati V., Baccarelli A. Environmental epigenetics // Heredity. 2010. Vol. 105 (1). P. 105. doi: https://doi.org/10.1038/hdy.2010.2

6. Circulating liver−specific microRNAs as noninvasive diagnostic biomarkers of hepatic diseases in human / G. Musaddaq, N. Shahzad, M. A. Ashraf, M. I. Arshad // Biomarkers. 2019. Vol. 24 (2). P. 103−109. doi: https://doi.org/10.1080/1354750X.2018.1528631. Epub 2018 Oct 23. PMID: 30252499

7. Kozomara A., Birgaoanu M., Griffiths−Jones S. miRBase: from microRNA sequences to function // Nucleic Acids Research. 2019. № 47. P. D155−D162. doi: https://doi.org/10.1093/nar/gky1141

8. Chiraz Atri, Fatma Z. Guerfali, Dhafer Laouini. MicroRNAs in diagnosis and therapeutics // AGO−Driven Non−Coding RNAs. Chapter 6. 2019. P. 137−177. doi: https://doi.org/10.1016/B978−0−12−815669−8.00006−3

9. Miravirsen dosing in chronic hepatitis C patients results in decreased microRNA−122 levels without affecting other microRNAs in plasma / M. H. Ree et al. // Aliment. Pharmacol. Ther. 2016. Vol. 43. P. 102−113. doi: https://doi.org/10.1111/apt.13432

10. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases / X. Chen et al. // Cell Res. 2008. № 18. R. 997−1006. doi: https://doi.org/10.1038/cr.2008.282

11. Shevchenko−Makarenko O. P. Uroven' ekspressii mikroRNK−29a u bol'nykh khronicheskim virusnym gepatitom S // Klinicheskaya infektologiya i parazitologiya. 2019. T. 8, № 2. S. 229−235.

12. Shostakovich−Korets'ka L. R., Shevchenko−Makarenko O. P., Lapikova−Brigins'ka T. Yu. Bazovii rіven' ekspresії mіkroRNK−196a u khvorikh na khronіchnii vіrusnii gepatit S z pershim genotipom HCV // Gepatologіya. 2019. №2 (44). S. 35−44. URL: http://nbuv.gov.ua/UJRN/gepat_2019_2_7